Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 ETF — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Vanguard S&P 500 ETF trades at $715.2 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 2151.3× Sana Biotechnology Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vanguard S&P 500 ETF for 55 Days on average.
| SANA | VOO | |
|---|---|---|
Market Cap | $836.71M | $1.80T |
Volume | 4,507,444 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $716.17 |
52-Week Low | $2.68 | $580.93 |
Typical Hold Time | 23 Days | 55 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
VOO trades at $713.62, down slightly by 0.11% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building through capital growth rather than dividends, with one article positioning it as a recession-resistant holding.
VOO offers diversified exposure to S&P 500 companies with strong institutional backing. Key risks include market volatility from interest rate uncertainty and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a core holding for long-term investors despite short interest increasing 46.9% in September.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
